Form D · Pharmaceuticals
Alveus Therapeutics, Inc.
Philadelphia, PA · CIK 0002075856
Offering snapshot reported Jan 14, 2026 · SEC filing
- Reported sold
- $56.9M Offering amount: $111M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 22, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 14, 2026 | Initial | $56,862,480 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-569872
Source: Form D, filed Jan 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carlo De Notaristefani | Director |
| Ivan Gergel | Director |
| Garrett Ingram | Director |
| Raj Kannan | Director, Executive |
| Ameet Nathwani | Director |
| Claudio Nessi | Director |
| Gregory Parekh | Director |
| Jan Van De Bossche | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
100 N. 18 Th Street, Suite 1930
Philadelphia, PA, 19103
Phone: 215-419-7830
Philadelphia, PA, 19103
Phone: 215-419-7830